The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma
Article first published online: 8 APR 2009
Copyright © 2009 John Wiley & Sons, Ltd.
Volume 28, Issue 1, pages 27–32, March 2010
How to Cite
Hyo, R., Tomita, N., Takeuchi, K., Aoshima, T., Fujita, A., Kuwabara, H., Hashimoto, C., Takemura, S., Taguchi, J., Sakai, R., Fujita, H., Fujisawa, S., Ogawa, K., Motomura, S., Suzuki, R. and Ishigatsubo, Y. (2010), The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol. Oncol., 28: 27–32. doi: 10.1002/hon.896
- Issue published online: 15 MAR 2010
- Article first published online: 8 APR 2009
- Manuscript Accepted: 13 JAN 2009
- Manuscript Revised: 3 JAN 2009
- Manuscript Received: 14 DEC 2008
The prognosis of diffuse large B-cell lymphoma (DLBCL) has improved markedly in recent years of rituximab era. The prognosis of de novo CD5-positive DLBCL is reported to be poor, but the effect of rituximab on this type of lymphoma remains unclear. To investigate the effect of rituximab on CD5-positive DLBCL, we collected DLBCL patients and analysed prognostic factors. A total of 157 patients with DLBCL who were immunophenotyped with flow-cytometry (FCM) and treated with chemotherapy were subjected to analysis. Those treated with radiotherapy alone or with supportive therapy only were not included. Patients diagnosed in 2003 or later were treated with rituximab combined chemotherapy. There were 95 males and 62 females. Their age ranged from 20 to 91 years old, and the median was 65 years. Nineteen patients were diagnosed as having de novo CD5-positive DLBCL. Rituximab was given alongside chemotherapy in 85 patients. Of these, 11 were positive for CD5 and 74 were negative. The addition of rituximab improved the overall survival (OS) of DLBCL patients (2-year OS: 82% vs. 70%, p = 0.01). For CD5-negative DLBCL, patients treated with rituximab showed 2-year OS of 84%, which was significantly better than those treated without rituximab (70%, p = 0.008). However, for CD5-positive DLBCL, the prognosis was not statistically different between the patients treated with and without rituximab (59% vs. 50%, p = 0.72). Although rituximab improved the prognosis of DLBCL, such improvement was restricted to the CD5-negative group. Further investigation is required to improve the prognosis of patients with CD5-positive DLBCL. Copyright © 2009 John Wiley & Sons, Ltd.